Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

Key Findings

• ●Tocilizumab significantly improved systemic feature score (p=0.003) and glucocorticoid sparing (p=0.017)
• ●ACR50 at week 4: 61.5% tocilizumab vs 30.8% placebo

Referenced in (1 disease)